Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III cardiovascular safety study of dutogliptin in type 2 diabetes mellitus
2009-017266-23Phase 3Terminated
- Sponsor
- Forest Research Institute
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dutogliptin arm with Placebo arm (2 arms). Primary endpoint: Incidence of major adverse cardiovascular events (MACEs) while on treatment or within 30 days after last dose. Started Mar 2010; status: terminated.
02
Drugs
dutogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-017266-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017266-23.